Success Metrics

Clinical Success Rate
46.2%

Based on 6 completed trials

Completion Rate
46%(6/13)
Active Trials
0(0%)
Results Posted
50%(3 trials)
Terminated
7(50%)

Phase Distribution

Ph phase_2
4
29%
Ph phase_1
4
29%
Ph phase_3
6
43%

Phase Distribution

4

Early Stage

4

Mid Stage

6

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
4(28.6%)
Phase 2Efficacy & side effects
4(28.6%)
Phase 3Large-scale testing
6(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

46.2%

6 of 13 finished

Non-Completion Rate

53.8%

7 ended early

Currently Active

0

trials recruiting

Total Trials

14

all time

Status Distribution
Completed(6)
Terminated(7)
Other(1)

Detailed Status

Terminated7
Completed6
unknown1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
0
Success Rate
46.2%
Most Advanced
Phase 3

Trials by Phase

Phase 14 (28.6%)
Phase 24 (28.6%)
Phase 36 (42.9%)

Trials by Status

terminated750%
unknown17%
completed643%

Recent Activity

0 active trials
Showing 5 of 14
completedphase_1

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

NCT00660218
unknownphase_3

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

NCT00108745
terminatedphase_3

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

NCT00269828
terminatedphase_3

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

NCT00054184
terminatedphase_3

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

NCT00551733
View all 14 trials

Clinical Trials (14)

Showing 14 of 14 trials
NCT00660218Phase 1

A Phase I/II Study of Radiation Therapy, Paclitaxel Poliglumex and Cetuximab in Advanced Head and Neck Cancer

Completed
NCT00108745Phase 3

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Unknown
NCT00269828Phase 3

A Survival Study for Women With Advanced Lung Cancer Who Have Not Previously Received Chemotherapy.

Terminated
NCT00054184Phase 3

Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer

Terminated
NCT00551733Phase 3

Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Terminated
NCT00054210Phase 3

Polyglutamate Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Terminated
NCT00054197Phase 3

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Terminated
NCT00045682Phase 2

CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed
NCT00459810Phase 2

Paclitaxel Poliglumex and Estradiol in Treating Patients With Stage IV Prostate Cancer

Terminated
NCT00352690Phase 2

A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer

Terminated
NCT00265733Phase 2

Paclitaxel Poliglumex and Capecitabine in Treating Patients With Metastatic Breast Cancer

Completed
NCT00060359Phase 1

Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Completed
NCT00598247Phase 1

A Pilot Study of PPX in Women With Metastatic Colorectal Cancer

Completed
NCT00017017Phase 1

CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14